Netherlands · 
What does Inkef invest in?
Inkef invests most often at Series A and Series B (80% of the rounds on record), in sectors such as Connected Health, Longevity and E-health.
Inkef highlights
- 01
3 cheques in the last 12 months
- 02
Mostly Series A and Series B: 80% of its rounds
- 03
Sole investor in 3 rounds, median $3.9M
- 04
1 exits from the portfolio
What they do
We are an early-stage, hands-on investor.From their own website
- Type
- VC firm (from a list, unverified)
- Cheque size
- $100K – $50M as they say
- Stages
- SeedSeries ASeries BGrowth
- Sectors
- Connected HealthLongevityE-health
- Based in
- Amsterdam, Netherlands
- Cold pitches
- Not stated
The record
Every round we can evidence, newest first20 appearances
- 2026
2 rounds
- May
- Mar
- 2025
3 rounds
- Dec
- Jun
- May
- 2023
1 round
- Nov
- 2019
4 rounds
- Oct
- Jun
- Feb
- Jan
- 2018
3 rounds
- Jul
- May
- Apr
- 2017
1 round
- Feb
- 2015
4 rounds
- Sept
- Sept
- Jun
- Jan
- 2014
1 round
- Jun
- 2012
1 round
- Nov
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
We hold 2 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
What the register says
From the firm's own filings with the SEC, which it must file accurately by law
5+funds on filenumbered funds in its name
What they claim to have backed
From their own portfolio page (on their website)
29 of 35 we have independently watched raise
AidenceAudion TherapeuticsBaserowBlendleBloomonCardiorChannelEngineDraupnir BioEclecticIQGeoPhyHappeoIoncturaLengooNMD PharmaOnefitPolarstepsQuantum MotionQurAlisRemoteSalvia BioElectronicsScenic BiotechShapewaysSilverflowTargED BiopharmaceuticalsUrban Sports ClubViCentraWellhubWerckerWithlocalsCastorCorporis MedicalNPEXOnwardProvable LabsRobin Radar
Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.
Exits from the portfolio
Companies it backed that were later bought or listed1 in all
Lanthio PharmaBought by MorphoSys$23MMay 2015
An exit counts when it came after the firm's first round in the company. From historical deal records.